Company
Every investor coverage indicates participated in a round Servier raised.
Companies Servier acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Servier. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of scientist-entrepreneur Andrew Wilks tracing his path from cancer research to founding drug developer Cytopia and launching SYNthesis BioVentures, a therapeutics fund that recently secured $30 million from wealthy individuals and family offices.
Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.
Also Forbes Australia